Review
Pharmacology & Pharmacy
Chayanis Kositamongkol, Sukrit Kanchanasurakit, Chiraphong Auttamalang, Nutkamon Inchai, Thanatchaporn Kabkaew, Sarunporn Kitpark, Nathorn Chaiyakunapruk, Acharaporn Duangjai, Surasak Saokaew, Pochamana Phisalprapa
Summary: The study results indicate that regular coffee consumption is associated with a lower incidence of NAFLD in the general population, but there is still some uncertainty in the findings. However, for patients with NAFLD, coffee intake is beneficial in reducing the risk of liver fibrosis. Additionally, there were no significant differences in coffee consumption among patients with different levels of liver fibrosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Endocrinology & Metabolism
Chen Liang, Zhiyuan Yu, Li Bai, Wei Hou, Shan Tang, Wei Zhang, Xinyue Chen, Zhongjie Hu, Zhongping Duan, Sujun Zheng
Summary: This study evaluated the association between serum bilirubin levels and metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD). The results showed an inverse correlation between serum total bilirubin (TBIL) and direct bilirubin (DBIL) levels with MetS in healthy population. Serum indirect bilirubin (IBIL) levels were inversely associated with the onset and degree of non-alcoholic steatohepatitis (NASH) in NAFLD patients. Exogenous bilirubin supplement may be a potential strategy to lower the risk of developing MetS and NAFLD.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Nutrition & Dietetics
Mattia Coronati, Francesco Baratta, Daniele Pastori, Domenico Ferro, Francesco Angelico, Maria Del Ben
Summary: Studies have found that fructose added to foods via high fructose corn syrup and sucrose could contribute to the onset and progression of NAFLD and MetS. Fructose affects liver function through multiple pathways, including inducing de novo lipogenesis, triggering endoplasmic reticulum stress and liver inflammation, reducing fatty acids oxidation, and increasing intestinal permeability. In addition, fructose intake is also associated with weight gain and hypertension.
Review
Biochemistry & Molecular Biology
Carlos Jimenez-Cortegana, Alba Garcia-Galey, Malika Tami, Pilar del Pino, Isabel Carmona, Soledad Lopez, Gonzalo Alba, Victor Sanchez-Margalet
Summary: NAFLD affects a quarter of the global population and poses a significant health and economic burden across all countries. The lack of approved pharmacotherapy and well-established diagnostic strategies for this disease highlights the urgency for further research and management efforts. Studies have shown a strong relationship between the hormone leptin and the development of NAFLD, suggesting potential advancements in disease management through further investigation of its role.
Review
Biochemistry & Molecular Biology
Luca Rinaldi, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Maria Vittoria Morone, Chiara Silvestri, Mauro Giordano, Teresa Salvatore, Ferdinando Carlo Sasso
Summary: Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) share similar features, with insulin resistance being a key factor. Lifestyle changes can improve symptoms, and there is a correlation between diabetes and multiorgan damage.
Article
Nutrition & Dietetics
Catalina M. Mascaro, Cristina Bouzas, Josep A. Tur
Summary: This systematic review assesses the effect of Mediterranean lifestyle on the prevention and reversal of non-alcoholic fatty liver disease (NAFLD). The findings indicate that following a Mediterranean diet and engaging in regular physical activity is associated with improved clinical parameters and NAFLD/MetS. Therefore, adopting a Mediterranean lifestyle is an effective approach for the prevention and treatment of NAFLD.
Review
Gastroenterology & Hepatology
Gowthami Sai Kogilathota Jagirdhar, Rakhtan K. Qasba, Harsha Pattnaik, Kaanthi Rama, Akshat Banga, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal, Yatinder Bains, Theodore DaCosta, Salim Surani
Summary: Our meta-analysis found that NAFLD/MAFLD patients have increased odds of hospitalization, longer hospital length of stay, and increased use of supplemental oxygen.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Medicine, General & Internal
Anna Pia Delli Bovi, Francesca Marciano, Claudia Mandato, Maria Anna Siano, Marcella Savoia, Pietro Vajro
Summary: This article discusses the interplay between oxidative stress and other pathogenic factors in non-alcoholic fatty liver disease (NAFLD), emphasizing the importance of reactive oxygen species (ROS) in NAFLD progression. It also points out the effectiveness of healthy diet and physical activity in NAFLD treatment, but lack of compliance, and the potential of precision medicine in selecting the best treatment for specific patients.
FRONTIERS IN MEDICINE
(2021)
Article
Endocrinology & Metabolism
Emir Muzurovic, Dimitri P. Mikhailidis, Christos Mantzoros
Summary: NAFLD is closely related to insulin resistance, metabolic syndrome, and cardiovascular disease risk, but its independent impact on the development of cardiovascular disease remains controversial.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Medicine, General & Internal
Manuela Abbate, Catalina M. Mascaro, Sofia Montemayor, Miguel Casares, Cristina Gomez, Lucia Ugarriza, Silvia Tejada, Itziar Abete, Maria Angeles Zulet, Antoni Sureda, J. Alfredo Martinez, Josep A. Tur
Summary: This study found an association between kidney glomerular hyperfiltration and NAFLD in adults with MetS, where the presence of NAFLD and increased weight were independently associated with an increased probability of presenting hyperfiltration. Establishing this association may help identify patients at increased risk of CKD who would benefit from early intervention.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Dana Ivancovsky-Wajcman, Naomi Fliss-Isakov, Muriel Webb, Itay Bentov, Oren Shibolet, Revital Kariv, Shira Zelber-Sagi
Summary: High consumption of ultra-processed food is associated with an increased risk of metabolic syndrome and NAFLD-related liver damage. Smoking may further increase the risk of significant fibrosis among individuals with NAFLD.
LIVER INTERNATIONAL
(2021)
Article
Nutrition & Dietetics
Catalina M. Mascaro, Cristina Bouzas, Sofia Montemayor, Miguel Casares, Cristina Gomez, Lucia Ugarriza, Pere-Antoni Borras, Jose Alfredo Martinez, Josep A. Tur
Summary: MetS patients with high PA showed a more positive relationship in NAFLD, MetS parameters, and liver profile (ALT, GGT, IFC-NMR) compared to those with low PA, but not for AST. The difference between calories ingested and expended influenced this relationship.
Article
Biochemistry & Molecular Biology
Miguel D. Ferrer, Clara Reynes, Margalida Monserrat-Mesquida, Magdalena Quetglas-Llabres, Cristina Bouzas, Silvia Garcia, David Mateos, Miguel Casares, Cristina Gomez, Lucia Ugarriza, Josep A. Tur, Antoni Sureda, Antoni Pons
Summary: Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of hepatic fat. This study investigated the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA), and markers of lipid peroxidation in NAFLD patients. The results showed that severe NAFLD patients had higher levels of oxylipins, saturated oxylipins, and free PUFA, suggesting an association between inflammation, fatty acid oxidation dysregulation, and NAFLD progression.
Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong-Ho Lee, Ji-Hye Kim, Seung Up Kim
Summary: There is an association between metabolic dysfunction-associated fatty liver disease (MAFLD) or NAFLD and cardiovascular disease (CVD) risk, with MAFLD potentially being a better identifier for CVD risk than NAFLD. Fibrosis assessment can provide helpful prognostic information for subjects with MAFLD.
LIVER INTERNATIONAL
(2023)
Review
Gastroenterology & Hepatology
Terry Cheuk-Fung Yip, Eduardo Vilar-Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai-Hung Wong, Leon A. Adams, Victor de Ledinghen, Silvia Sookoian, Vincent Wai-Sun Wong
Summary: NAFLD has become a major public health problem with diverse disease burden across geographical areas and ethnicities. The associated comorbidities and complications have a significant impact on patients' quality of life, healthcare systems, and economy.
Article
Gastroenterology & Hepatology
Yusuf Yilmaz, Ahmet Eren Toraman, Ceyda Alp, Zehra Dogan, Caglayan Keklikkiran, Maria Stepanova, Zobair Younossi
Summary: Patients with more advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Several non-invasive tests (NITs) for fibrosis are associated with PROs. The PRO scores of patients with NAFLD are lower than those of matched patients with chronic hepatitis B.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Yusuf Yilmaz, Zobair Younossi
Summary: This article is related to the papers of Yilmaz et al. To access these papers, please visit the link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Arun J. Sanyal, Julie Foucquier, Zobair M. Younossi, Stephen A. Harrison, Philip N. Newsome, Wah-Kheong Chan, Yusuf Yilmaz, Victor De Ledinghen, Charlotte Costentin, Ming-Hua Zheng, Vincent Wai-Sun Wong, Magdy Elkhashab, Ryan S. Huss, Robert P. Myers, Marine Roux, Aymeric Labourdette, Marie Destro, Celine Fournier-Poizat, Veronique Miette, Laurent Sandrin, Jerome Boursier
Summary: This study aims to develop and validate two new scoring systems (Agile 4 and Agile 3+) to accurately identify cirrhosis or advanced fibrosis among individuals with non-alcoholic fatty liver disease (NAFLD) attending liver clinics. The results showed that these two novel non-invasive scores outperformed existing scoring systems in identifying cirrhosis or advanced fibrosis and reduced the need for liver biopsy.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zobair M. Younossi, Ming-Lung Yu, Yusuf Yilmaz, Khalid Aida Alswat, Maria Buti, Marlen Ivon Castellanos Fernandez, Georgios Papatheodoridis, Saeed S. Hamid, Mohamed El-Kassas, Wah Kheong Chan, Ajay K. Duseja, Stuart C. Gordon, Yuichiro Eguchi, Vasily A. Isakov, Stuart K. Roberts, Jian-Gao Fan, Ashwani K. Singal, Manuel Romero-Gomez, Aijaz Ahmed, Janus Ong, Brian P. Lam, Issah Younossi, Fatema Nader, Andrei Racila, Maria Stepanova, Saleh Alqahtani
Summary: Chronic hepatitis B (CHB) infection is a common cause of cirrhosis and liver cancer worldwide. The Global Liver Registry is being used to assess the clinical and patient-reported outcomes (PROs) of CHB patients from different regions. The study included 1818 CHB patients from 15 countries, with varying rates of advanced fibrosis. HBV subjects from the Middle East/North Africa had the lowest PRO scores, while those from Southeast/East and South Asia had the highest. Factors associated with PRO impairment in CHB patients included advanced fibrosis, non-hepatic comorbidities, and female sex.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Gastroenterology & Hepatology
Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Virend Somers, Seung Up Kim, C. Anwar A. Chahal, Vincent Wai-Sun Wong, Jingjing Cai, Michael D. Shapiro, Mohammed Eslam, Philippe Gabriel Steg, Ki-Chul Sung, Anoop Misra, Jian-Jun Li, Carlos Brotons, Yuli Huang, George V. Papatheodoridis, Aijun Sun, Yusuf Yilmaz, Wah Kheong Chan, Hui Huang, Nahum Mendez-Sanchez, Saleh A. Alqahtani, Helena Cortez-Pinto, Gregory Y. H. Lip, Robert J. de Knegt, Ponsiano Ocama, Manuel Romero-Gomez, Marat Fudim, Giada Sebastiani, Jang Won Son, John D. Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupsor-Platon, Herbert Tilg, Hasmik Ghazinyan, Jerome Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian-Gao Fan, George Boon-Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming-Hua Zheng
Summary: Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is closely linked to cardiovascular disease (CVD), but the CVD risk is often underestimated. An international panel of experts conducted a Delphi survey to establish the association between MAFLD and CVD risk, and identified potential areas for future research.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Graciela E. Castro-Narro, Helena Cortez-Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven M. Francque, Hannes Hagstrom, Terry T. -K. Huang, Dana Ivancovsky Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Veronica Miller, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C. Wendy Spearman, Emmanuel A. Tsochatzis, Luca Valenti, Marcela Villota-Rivas, Shira Zelber-Sagi, Jorn M. Schattenberg, Vincent Wai-Sun Wong, Zobair M. Younossi
Summary: This study aimed to develop a research agenda for fatty liver disease, and 28 priorities were identified to address the individual and societal harms caused by this disease. Adopting this agenda can accelerate global efforts to respond to this public health threat.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Gong Feng, Luca Valenti, Vincent Wai-Sun Wong, Yasser Mahrous Fouad, Yusuf Yilmaz, Won Kim, Giada Sebastiani, Zobair M. Younossi, Virginia Hernandez-Gea, Ming-Hua Zheng
Summary: This article discusses the importance of recompensation in the field of cirrhosis, particularly in NAFLD-related cirrhosis. It provides an up-to-date perspective on the natural history of NAFLD, emphasizing its reversible nature, and discusses the mechanisms and challenges of recompensation, as well as outlining future research directions.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz
Summary: This study retrospectively evaluated the demographic characteristics, etiologies of chronic liver disease, and FibroScan (R) parameters of patients referred to a tertiary care center between 2013 and 2021. The results showed that nonalcoholic fatty liver disease was the most common indication for referral, followed by hepatitis B and hepatitis C.
Article
Gastroenterology & Hepatology
Ayse Sakalli Kani, Ahmet Ozercan, Haluk Tarik Kani, Fatih Eren, Kemal Sayar, Yusuf Yilmaz
Summary: This study aimed to investigate the variations in chronotype, night-eating patterns, and sleep quality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and analyze their correlation with disease severity and fibrosis. The results showed that patients with non-morningness chronotype had poorer sleep quality and a higher prevalence of night-eating behavior. In addition, age and poor sleep quality significantly impacted the presence of advanced fibrosis.
Meeting Abstract
Gastroenterology & Hepatology
Zobair M. Younossi, Marlen Castellanos Fernandez, Yusuf Yilmaz, Ming-Lung Yu, Mohamed El-Kassas, Gamal Esmat, Vasily Isakov, Vincent Wong, Yuichiro Eguchi, Khalid Alswat, Nahum Mendez-Sanchez, Ajay Duseja, Maria Buti, George Papatheodoridis, Saeed S. Hamid, Jacob George, Elisabetta Bugianesi, Wah-Kheong Chan, Ashwani K. Singal, Stuart C. Gordon, Jian Gao Fan, Manuel Romero-Gomez, Stuart K. Roberts, Janus Ong, Brian P. Lam, Marcelo Kugelmas, Issah M. Younossi, Fatema Nader, Andrei Racila, Maria Stepanova, Saleh A. Alqahtani
Meeting Abstract
Gastroenterology & Hepatology
Zobair Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vasily Isakov, Marlen Ivon Castellanos Fernandez, Vincent Wai-Sun Wong, Yuichiro Eguchi, Nahum Mendez-Sanchez, Ajay Kumar Duseja, Jacob George, Elisabetta Bugianesi, Ashwani Singal, Saeed Sadiq Hamid, Jian-Gao Fan, Khalid Alswat, George Papatheodoridis, Mohamed El Kassas, Wah-Kheong Chan, Stuart C. Gordon, Manuel Romero Gomez, Stuart Roberts, Brian Lam, Issah Younossi, Andrei Racila, Linda Henry, Saleh Alqahtani, Maria Stepanova
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Zobair Younossi, Yusuf Yilmaz, Jian-Gao Fan, Vincent Wai-Sun Wong, Mohamed El Kassas, Shira Zelber-Sagi, Alina Allen, Mary Rinella, Ashwani Singal, Stuart C. Gordon, Michael Fuchs, Wayne Eskridge, Naim Alkhouri, Khalid Alswat, Hirokazu Takahashi, Takumi Kawaguchi, Jane Ranagan, Ming-Hua Zheng, Ajay Kumar Duseja, Patrizia Burra, Carrieri Patrizia, Marco Arrese, Achim Kautz, Janus Ong, Laurent Castera, Sven Francque, Marcelo Kugelmas, Yuichiro Eguchi, Sombat Treeprasertsuk, Marlen Ivon Castellanos Fernandez, Manuel Romero Gomez, Philip N. Newsome, Kenneth Cusi, Rohit Loomba, Jorn Schattenberg, Ming-Lung Yu, Moises Diago, Lynn Gerber, Brian Lam, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Saleh Alqahtani, Jeffrey Lazarus
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Ilkay Ergenc, Hasan Yapici, Caglayan Keklikkiran, Yusuf Yilmaz
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yusuf Yilmaz, Mujdat Zeybel, Gupse Adali, Arif Mansur Cosar, Elif Sertesen, Hale Gokcan, Halil Ibrahim Bahcecioglu, Mustafa Sahin, Cansin Tulunay, Ihsan Ergun, Ilker Turan, Ilkay Sedakat Idilman, Cigdem Celikel, Hale Kirimlioglu, Gulen Akyol, Funda Yilmaz, Cenk Sokmensuer, Hakan Guveli, Ulus Salih Akarca, Umit Akyuz, Volkan Genc, Murat Akyildiz, Nuray Yazihan, Engin Tutar, Fehmi Ates, Dinc Dincer, Yasemin Balaban, Murat Kiyici, Meral Akdogan, Abdullah Sonsuz, Ramazan Idilman
Summary: Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. This guidance aims to provide a standardized approach to diagnosing and treating NAFLD patients and reflects the advances in the field.